Drug combo for newly diagnosed acute myeloid leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of three drugs (venetoclax, homoharringtonine, and azacitidine) plus a growth factor to treat newly diagnosed AML in people who aren't strong enough for standard chemo. The goal is to see if this combo can help control the leukemia with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have newly diagnosed acute myeloid leukemia (AML) that has not been treated yet.
- You must be 75 years or older, or be 18-74 with health problems that make standard strong chemo too risky (like heart, lung, or kidney issues).
- Your kidneys must work at least moderately well (creatinine clearance at least 30).
- Your liver tests must be within certain limits (AST and ALT no more than 3 times the normal upper limit).
- You must not have a history of other blood cancers like myelofibrosis or previous treatment for MDS with certain drugs.
- You must be willing to avoid grapefruit, Seville oranges, and star fruit for 3 days before each dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs for people with acute myeloid leukemia (AML) whose cancer did not respond to or stopped responding to the usual first-line treatment. The goal is to see if this new approach can help where the previous one didn't.
This study tests a combination of three drugs—aclarubicin, azacitidine, and venetoclax—for people with acute myeloid leukemia (AML) who cannot have intensive chemotherapy, or whose leukemia has returned after treatment. The goal is to see if this combination helps control the leukemia with manageable side effects.
This trial tests a combination of three drugs for treating newly diagnosed AML in older or frailer patients. The goal is to see if this combination is safe and effective, providing a gentler option for those who cannot handle standard intensive chemotherapy.
This trial tests a combination of three drugs (venetoclax, azacitidine, and homoharringtonine) followed by a donor stem cell transplant for people with intermediate- or high-risk acute myeloid leukemia (AML). The goal is to see if this approach can improve outcomes for patients who have not been treated before.
This trial studies whether adding venetoclax to standard induction chemotherapy (homoharringtonine plus cytarabine) can improve outcomes for people with newly diagnosed AML. It mainly looks at people who can safely receive intensive chemotherapy but have certain heart, kidney, or lung limits.
This trial tests a new combination of drugs (VA plus HAAG) for adults newly diagnosed with intermediate or high-risk AML. It aims to see if this combination is safe and effective for people who haven't had prior treatment.
Hear when a new Acute Myeloid Leukemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.